The emergence of compounds like copyright and Semaglutide signifies a remarkable shift in how we manage type 2 diabetes. These groundbreaking therapies belong to a class known as GLP-1 receptor agonists, which mimic the effects of a natural hormone that controls blood sugar levels and appetite. First, developed for diabetic conditions, their effect